These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 7146725)

  • 1. Effects of tiapride in tardive dyskinesia.
    Pollak P; Gaio JM; Hommel M; Pellat J; Perret J
    Psychopharmacology (Berl); 1985; 85(2):236-9. PubMed ID: 3925489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
    Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
    Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biphasic effect of apomorphine on rat nociception and effect of dopamine D2 receptor antagonists.
    Pelissier T; Laurido C; Hernandez A; Constandil L; Eschalier A
    Eur J Pharmacol; 2006 Sep; 546(1-3):40-7. PubMed ID: 16905131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acute effect of haloperidol and apomorphine on the severity of stuttering.
    Burns D; Brady JP; Kuruvilla K
    Biol Psychiatry; 1978 Apr; 13(2):255-64. PubMed ID: 667231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the anti-dyskinesia effect of apomorphine in man.
    Tolosa ES
    Neurol Neurocir Psiquiatr; 1976; 17(4):223-9. PubMed ID: 138800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic effect of estradiol and domperidone on lingual dyskinesia in monkeys.
    Bédard P; Boucher R; Di Paolo T; Labrie F
    Exp Neurol; 1983 Oct; 82(1):172-82. PubMed ID: 6628606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Modification of extrapyramidal signs by apomorphine associated with various dopaminergic antagonists].
    Pollak P; Gaio JM; Hommel M; Pellat J; Perret J; Chateau R
    Rev Neurol (Paris); 1982; 138(5):409-13. PubMed ID: 7146725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Duality of dopaminergic receptors. Pharmacologic and clinical perspectives].
    Marais C
    Sem Hop; 1978 May; 54(13-16):563-7. PubMed ID: 211603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine in the treatment of Parkinson disease and other movement disorders.
    Gunzler SA
    Expert Opin Pharmacother; 2009 Apr; 10(6):1027-38. PubMed ID: 19364250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine autoreceptor stimulation: clinical significance.
    Meltzer HY
    Pharmacol Biochem Behav; 1982; 17 Suppl 1():1-10. PubMed ID: 6223322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian drugs: pharmacological and therapeutic aspects.
    Calne DB; Reid JL
    Drugs; 1972; 4(1):49-74. PubMed ID: 4405376
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.